Syndax Pharmaceuticals (FRA:1T3) Valuation Rank


FRA:1T3 Syndax Pharmaceuticals Inc FRA:1T3
25 GF Score
Price €19.11
! 9 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Syndax Pharmaceuticals Valuation Rank Related Terms

FRA:1T3
25GF Score
Syndax Pharmaceuticals Inc FRA:1T3
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA1T3:Germany
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
25GF Score

Get the complete analysis for FRA:1T3

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.11
Price